GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

John Mauldin's Investing in the New Normal - Featuring Bass, El-Erian, Hussman

June 12, 2013 | About:
Canadian Value

Canadian Value

115 followers
John Mauldin put together a tremendous group of financial market participants to discuss the investing environment today.

The group consisted of the following individuals:

kyle-bass.jpg

J Kyle Bass

Managing Member, Hayman Capital Management

Rose to fame with prescient bets against the residential housing market before the 2008 financial crisis.

mohamed-el-erian.jpg

Mohamed El-Erian

CEO, PIMCO

Dr. Mohamed A. El-Erian is CEO and co-CIO of PIMCO, the global investment management firm with $1.9 trillion of assets under management.

john-mauldin.jpg

John Mauldin

Chairman, Mauldin Economics

World-renowned economist and financial writer of the New York Times best-selling books "Bull's Eye Investing," "Just One Thing" and "Endgame."

barry-ritholtz.jpg

Barry Ritholtz

Chief Investment Officer, The Ritholtz Group/Fusion Analytics

Noted investment strategist and author of the book "Bailout Nation." Barry L. Ritholtz is one of the few strategists who saw the coming housing implosion and derivative mess far in advance.

david-rosenburg.jpg

David Rosenberg

Chief Economist & Strategist, Gluskin Sheff + Associates Inc.

Often ranked as an Institutional Investor All-Star and named the most accurate economic forecaster of 2011 by MSNBC.

The link below takes you to the video and you just need to provide an e-mail address to watch:

http://www.mauldineconomics.com/

About the author:

Canadian Value
http://valueinvestorcanada.blogspot.com/

Rating: 2.7/5 (7 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK